Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
0.1626
Dollar change
+0.0013
Percentage change
0.81
%
Index- P/E- EPS (ttm)-0.35 Insider Own7.45% Shs Outstand98.85M Perf Week2.46%
Market Cap16.07M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float91.49M Perf Month1.69%
Income-28.06M PEG- EPS next Q- Inst Own39.32% Short Float0.23% Perf Quarter-25.07%
Sales47.36M P/S0.34 EPS this Y- Inst Trans-4.23% Short Ratio0.43 Perf Half Y-62.96%
Book/sh0.31 P/B0.53 EPS next Y- ROA-35.40% Short Interest0.21M Perf Year-88.94%
Cash/sh0.45 P/C0.36 EPS next 5Y- ROE-84.68% 52W Range0.14 - 1.53 Perf YTD-10.66%
Dividend Est.- P/FCF- EPS past 5Y-2.23% ROI-91.97% 52W High-89.37% Beta0.47
Dividend TTM- Quick Ratio2.05 Sales past 5Y2.99% Gross Margin94.47% 52W Low19.47% ATR (14)0.01
Dividend Ex-Date- Current Ratio2.05 EPS Y/Y TTM25.96% Oper. Margin-46.20% RSI (14)45.55 Volatility8.97% 8.08%
Employees144 Debt/Eq0.40 Sales Y/Y TTM66.17% Profit Margin-59.25% Recom1.67 Target Price7.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q16.88% Payout- Rel Volume0.50 Prev Close0.16
Sales Surprise- EPS Surprise- Sales Q/Q263.50% Earnings- Avg Volume501.30K Price0.16
SMA20-3.35% SMA50-3.33% SMA200-50.03% Trades Volume250,674 Change0.81%
Date Action Analyst Rating Change Price Target Change
Mar-13-20Upgrade Robert W. Baird Neutral → Outperform $5
Jul-30-19Downgrade Robert W. Baird Outperform → Neutral
May-14-19Initiated Robert W. Baird Outperform $5
Mar-19-18Initiated Jefferies Buy $12
Mar-19-18Initiated Evercore ISI Outperform $13
Jan-16-18Reiterated H.C. Wainwright Buy $9 → $12
May-30-17Initiated Rodman & Renshaw Buy $9
Aug-05-16Resumed ROTH Capital Buy
Aug-12-15Initiated JMP Securities Mkt Outperform
Jul-27-15Initiated Oppenheimer Outperform $8
Nov-14-23 05:36PM
Sep-25-23 12:00PM
Aug-24-23 12:32PM
Aug-23-23 12:00PM
Aug-17-23 08:00AM
02:02PM Loading…
Jul-19-23 02:02PM
08:40AM
Jul-18-23 01:59PM
09:15AM
Jul-17-23 07:29AM
Jun-23-23 10:50AM
Jun-21-23 07:00AM
Jun-11-23 10:28AM
Jun-02-23 04:30PM
May-22-23 08:00AM
08:00AM Loading…
May-21-23 08:00AM
May-15-23 06:07AM
May-11-23 01:41PM
May-10-23 08:15AM
07:00AM
May-05-23 06:41AM
May-04-23 08:00AM
May-02-23 04:30PM
Apr-17-23 08:00AM
Apr-01-23 12:47PM
Mar-31-23 06:10AM
Mar-29-23 05:00PM
08:35AM
07:00AM
Mar-24-23 05:00PM
07:39AM Loading…
Feb-19-23 07:39AM
Feb-14-23 05:40AM
Jan-17-23 07:10AM
Jan-10-23 08:00AM
Dec-21-22 06:01AM
Nov-23-22 08:00AM
Nov-09-22 08:00AM
Nov-02-22 08:35AM
07:00AM
Nov-01-22 09:15AM
Oct-26-22 08:00AM
Sep-12-22 08:03AM
Sep-08-22 04:01PM
Aug-24-22 10:34AM
08:00AM
Aug-10-22 06:20AM
Aug-04-22 02:03PM
09:35AM
07:00AM
Jul-28-22 07:20AM
Jul-14-22 06:29AM
Jun-02-22 08:00AM
May-18-22 09:35AM
08:00AM
May-16-22 09:35AM
08:29AM
May-11-22 08:45AM
07:00AM
May-04-22 08:00AM
Apr-15-22 11:00AM
Apr-09-22 06:00AM
Apr-08-22 06:15AM
Apr-05-22 12:00PM
Mar-04-22 04:00PM
Mar-01-22 11:05AM
07:00AM
Feb-28-22 09:25AM
Feb-23-22 08:00AM
Feb-04-22 08:58AM
Jan-28-22 08:00AM
Jan-27-22 06:23PM
Jan-16-22 10:30AM
Jan-14-22 08:00AM
Jan-03-22 07:00AM
Dec-15-21 12:53PM
Dec-06-21 09:33AM
Nov-11-21 08:05AM
Nov-08-21 08:00AM
Nov-02-21 09:05AM
07:00AM
Oct-26-21 08:00AM
Oct-14-21 10:00AM
Oct-06-21 08:00AM
Sep-09-21 08:00AM
Sep-08-21 10:31AM
Aug-27-21 10:40AM
Aug-24-21 09:00AM
Aug-06-21 09:42AM
Aug-04-21 09:25AM
07:00AM
Aug-03-21 08:00AM
Jul-28-21 08:00AM
Jun-30-21 08:31AM
Jun-25-21 09:24AM
07:00AM
06:18AM
05:23AM
Jun-24-21 10:03AM
08:00AM
Jun-19-21 05:34AM
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIRITSY CHRISTOPHER PDirectorMay 25Buy0.8510,0008,50020,000May 30 04:21 PM